Syu W J, Huang J H, Essex M, Lee T H
Department of Cancer Biology, Harvard University School of Public Health, Boston, MA 02115.
Proc Natl Acad Sci U S A. 1990 May;87(10):3695-9. doi: 10.1073/pnas.87.10.3695.
Human immunodeficiency virus (HIV) vaccines targeted at blocking HIV-CD4 interactions are expected to be less affected by the sequence heterogeneity of HIV than those targeted at variable regions of the envelope outercoat glycoprotein, gp120. All potential CD4 binding sites identified thus far in HIV are localized in the C-terminal region of gp120. In this study we demonstrate that the N-terminal region of gp120 also contains conserved residues critical for binding to CD4 and that gp120-CD4 interactions can be blocked by an antiserum with binding specificity to an N-terminal region of gp120. These results suggest that not all potential CD4 binding sites are present in the C-terminal region of gp120 and that an alternative HIV vaccine development strategy may have to include the N-terminal gp120 region as a component to raise effective CD4-blocking antibodies.
与针对包膜外膜糖蛋白gp120可变区的疫苗相比,旨在阻断HIV与CD4相互作用的人类免疫缺陷病毒(HIV)疫苗预计受HIV序列异质性的影响较小。迄今为止在HIV中鉴定出的所有潜在CD4结合位点都位于gp120的C末端区域。在本研究中,我们证明gp120的N末端区域也含有与CD4结合至关重要的保守残基,并且gp120与CD4的相互作用可被对gp120 N末端区域具有结合特异性的抗血清阻断。这些结果表明,并非所有潜在的CD4结合位点都存在于gp120的C末端区域,并且一种替代的HIV疫苗开发策略可能必须将gp120 N末端区域作为一个组成部分,以产生有效的CD4阻断抗体。